Adagene Inc.

https://investor.adagene.com

Adagene Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel antibody-based cancer immunotherapies. Incorporated in 2011 under the laws of the Cayman Islands, the company leverages computational biology and artificial intelligence to design innovative antibodies. Its corporate headquarters is located in Suzhou, Jiangsu Province, China.

The company's core technology is its proprietary AI-Powered Dynamic Precision Library (DPL) platform, which encompasses NEObody, SAFEbody, and POWERbody technologies. This platform enables the generation of therapeutic antibody candidates with unique functional epitopes. Adagene's pipeline includes lead product candidates such as ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, currently in clinical development for metastatic microsatellite-stable colorectal cancer. Other clinical-stage assets include ADG116, another anti-CTLA-4 antibody, and ADG106, an anti-CD137 agonist antibody, both targeting advanced solid tumors.

In recent news, Adagene received FDA Fast Track Designation in December 2025 for muzastotug (ADG126) in combination with pembrolizumab for adult patients with MSS metastatic colorectal cancer. The company has also established clinical collaborations, including one with Incyte to evaluate muzastotug in combination with Incyte's TGFβR2xPD-1 bispecific antibody for MSS CRC, with a Phase 1 study anticipated to commence in 2026. Furthermore, in July 2025, Sanofi made a strategic investment of up to $25 million in Adagene and exercised an option for a third SAFEbody discovery program, underscoring the potential of Adagene's platform and its lead programs. Dr. Peter Luo serves as the Co-founder, CEO, and Chairman of Adagene.

Latest updates

Adagene Data Shows Promise for Novel Immunotherapy Combinations in HCC, CRC

Event summary

  • Adagene presented data at AACR 2026 showing a 66.7% overall response rate (ORR) in locally advanced HCC patients treated with muzastotug + atezolizumab + bevacizumab, compared to 32.5% in the control arm.
  • A Phase 1b/2 trial in late-line MSS CRC patients demonstrated a dose-dependent ORR (25% and 40%) with muzastotug + pembrolizumab + fruquintinib.
  • The data suggest muzastotug’s masking technology reduces peripheral toxicity and allows for higher-dose anti-CTLA-4 therapy within the tumor microenvironment.
  • The FDA has granted Fast Track designation to muzastotug in combination with pembrolizumab for MSS mCRC patients.

The big picture

Adagene's data highlights the ongoing effort to overcome the limitations of existing immunotherapies by targeting the tumor microenvironment and reducing systemic toxicity. The company's SAFEbody technology represents a novel approach to immunotherapy development, and the positive early results suggest a potential pathway to broader adoption of combination regimens for difficult-to-treat cancers. Success here could position Adagene as a key player in the expanding oncology immunotherapy market, currently valued at tens of billions of dollars annually.

What we're watching

Clinical Validation
The durability of the observed response rates in both HCC and CRC will be critical to assess the long-term clinical benefit of muzastotug combinations, particularly given the limited follow-up data presented.
Regulatory Pathway
The success of Adagene’s ongoing Phase 2 trials will heavily influence the FDA’s assessment of muzastotug’s potential for accelerated approval, especially given the Fast Track designation.
Competitive Landscape
The emergence of muzastotug as a backbone therapy could shift the competitive dynamics within the crowded immunotherapy space, potentially impacting the market share of existing treatments like atezolizumab and pembrolizumab.

Adagene Bolsters Leadership with Oncology Veteran Lebowitz

Event summary

  • Adagene appointed Peter Lebowitz, former Global Head of Oncology R&D at Johnson & Johnson, to its Scientific and Strategic Advisory Board (SAB).
  • Lebowitz previously oversaw a research and development organization at J&J that delivered 13 new drugs and secured 12 FDA Breakthrough Therapy Designations.
  • Lebowitz's focus will be on guiding the clinical development of Adagene's lead program, ADG126, particularly strategies for registration-enabling studies.
  • ADG126 is a masked anti-CTLA-4 SAFEbody in Phase 1b/2 and Phase 2 trials for MSS metastatic colorectal cancer (CRC).

The big picture

Adagene's acquisition of Lebowitz signals a strategic push to accelerate the clinical development of its ADG126 program and expand the application of its SAFEbody technology. The company is attempting to address a significant unmet need in MSS CRC, where existing immunotherapies have shown limited efficacy. Lebowitz's track record of successfully navigating drug development and regulatory hurdles will be crucial for Adagene's success in a competitive oncology landscape.

What we're watching

Clinical Efficacy
The success of ADG126 in MSS CRC, a historically difficult-to-treat cancer, will be critical to validating Adagene's SAFEbody platform and attracting further investment.
Regulatory Pathway
Lebowitz’s experience will be tested as Adagene navigates registration-enabling studies; the FDA’s acceptance of Adagene’s novel masking approach could set a precedent for future immunotherapy development.
Platform Expansion
Adagene’s ability to leverage the SAFEbody platform beyond ADG126, particularly in combination therapies, will determine the long-term value of the technology.

Adagene Raises $70 Million in Oversubscribed ADS Offering

Event summary

  • Adagene Inc. (Nasdaq: ADAG) priced an offering of 18.67 million American Depositary Shares (ADSs) at $3.75 per ADS.
  • The offering is expected to close on April 6, 2026, and will generate approximately $70 million in gross proceeds.
  • New and existing investors, including Janus Henderson, Deerfield Management, and Invus, participated in the offering.
  • The offering was made under a shelf registration statement filed with the SEC on May 9, 2025.

The big picture

Adagene's capital raise reflects the ongoing demand for innovative cancer therapies, but also highlights the challenges faced by biotech companies in securing funding. The oversubscription indicates investor interest, but the pricing suggests a cautious approach given the current market environment. The involvement of several prominent investment firms signals a belief in Adagene's platform, but also introduces potential pressure for performance.

What we're watching

Capital Allocation
How Adagene utilizes the $70 million in proceeds will be critical; the company’s stated focus on antibody-based cancer immunotherapies suggests potential investments in clinical trials or platform expansion.
Investor Sentiment
The participation of established institutional investors like Janus Henderson and Deerfield Management signals a degree of confidence, but the $3.75 price point, below the VWAP, suggests potential concerns about valuation.
SAFEbody Tech
The success of Adagene’s SAFEbody precision masking technology, and its ability to attract strategic collaborations, will be a key determinant of long-term value creation.

Adagene, Incyte Partner on MSS CRC Therapy Combination

Event summary

  • Adagene and Incyte are collaborating to evaluate the combination of Adagene’s muzastotug (ADG126) and Incyte’s INCA33890 in patients with microsatellite stable colorectal cancer (MSS CRC).
  • A Phase 1 study is planned to begin in 2026, focusing on 3L MSS CRC patients with and without liver metastases, sponsored and conducted by Incyte.
  • Adagene will supply muzastotug for the clinical trial.
  • This collaboration represents the second instance of Adagene’s SAFEbody technology being paired with a PD-1 bispecific antibody.

The big picture

MSS CRC represents a significant unmet need in oncology, as existing immunotherapies have limited efficacy in this patient population. This collaboration highlights the ongoing effort to develop novel combination strategies to overcome resistance mechanisms. Adagene’s SAFEbody technology, if validated, could become a valuable platform for creating next-generation immunotherapies with improved safety profiles and broader applicability.

What we're watching

Clinical Efficacy
The initial Phase 1 data will be crucial in determining whether the combination demonstrates meaningful efficacy in MSS CRC, a notoriously difficult-to-treat cancer type.
SAFEbody Adoption
Further collaborations leveraging Adagene’s SAFEbody technology will indicate the broader appeal and value proposition of this masking approach in immuno-oncology.
Regulatory Pathway
The success of Incyte’s Phase 3 trial evaluating INCA33890 with standard chemotherapy will likely influence the development and regulatory pathway for the combination with muzastotug.

Adagene's Muzastotug Shows Promise in Late-Stage Colorectal Cancer

Event summary

  • Adagene's Phase 1b/2 study of muzastotug in combination with pembrolizumab (KEYTRUDA®) demonstrated a 31% overall response rate (ORR) in the 20 mg/kg dose cohort, compared to 13% in the 10 mg/kg cohort.
  • The 20 mg/kg cohort showed a median duration of response (mDOR) that was not yet reached, while the 10 mg/kg cohort had a mDOR of 6.2 months.
  • Median progression-free survival (PFS) was 6.7 months in the 20 mg/kg cohort versus 4.8 months in the 10 mg/kg cohort.
  • A randomized Phase 2 trial is currently enrolling patients, with results expected in 1H 2027, and a potential registration trial is planned following dose regimen establishment.

The big picture

MSS colorectal cancer represents a significant unmet medical need, with limited treatment options and poor outcomes. Adagene's approach of masking CTLA-4 antibodies to improve safety and efficacy addresses a key challenge in immunotherapy, potentially expanding the therapeutic window for this patient population. The Fast Track designation underscores the FDA's recognition of the potential benefit, but successful Phase 2 results are essential to realize this opportunity.

What we're watching

Clinical Efficacy
The success of the ongoing Phase 2 trial will be critical in validating the observed dose-dependent efficacy and establishing a clear path to registration, particularly given the differing results between the Q3W and Q6W regimens.
Regulatory Pathway
Adagene's ability to secure FDA feedback on the optimal dose regimen and navigate the registration process will heavily influence the program's timeline and commercial potential.
Competitive Landscape
The emergence of new therapies for MSS colorectal cancer will likely intensify competition, requiring Adagene to demonstrate a clear clinical and safety advantage for muzastotug.

Adagene Shows Promise in MSS CRC Trial, Burns Cash at a Rapid Pace

Event summary

  • Adagene reported 2025 revenue of $7.7 million, a significant increase from $0.1 million in 2024, primarily due to collaboration and licensing agreements.
  • Clinical trial data for muzastotug showed a 29% overall response rate (ORR) in MSS CRC patients at a 20mg/kg dose and a median overall survival (OS) of 19.4 months at 10mg/kg.
  • Adagene has $74.5 million in cash and cash equivalents, with an anticipated runway into early 2028, supplemented by proceeds from an ATM offering.
  • The company is accelerating enrollment in a Phase 2 dose-optimization study, aiming to begin a registration trial in 1H 2027.

The big picture

Adagene's progress with muzastotug represents a potentially significant advancement in treating microsatellite stable colorectal cancer, a historically difficult-to-treat indication. However, the company's rapid cash burn, while fueled by recent collaborations, highlights the inherent financial risks associated with clinical-stage biotechnology. The success of muzastotug hinges on demonstrating sustained efficacy and navigating the complex regulatory landscape.

What we're watching

Clinical Efficacy
The durability of the observed ORR and OS in the 20mg/kg cohort will be critical to validate the initial findings and inform the design of the registration trial.
Financial Sustainability
The pace of cash burn will need to moderate as Adagene advances its pipeline, and the success of future collaborations will be key to extending the runway.
Regulatory Alignment
Adagene’s continued alignment with FDA Project Optimus and ability to secure accelerated approval pathways will be essential for timely commercialization.

Adagene's CTLA-4 Masking Antibody Data to be Presented at AACR

Event summary

  • Adagene (ADAG) will present data on its lead clinical program, muzastotug (ADG126), at the 2026 AACR Annual Meeting in San Diego, CA, April 17-22.
  • Two poster presentations will focus on Phase 1b and Phase 1b/2 trials: one in combination with pembrolizumab and fruquintinib for colorectal cancer, and another in combination for hepatocellular carcinoma (HCC).
  • Muzastotug is a masked anti-CTLA-4 SAFEbody with FDA Fast Track designation, targeting Tregs in the tumor microenvironment.
  • The presentations will occur on April 20, 2026, between 9:00 AM and 12:00 PM Pacific Time.

The big picture

Adagene's approach to masking CTLA-4 to reduce toxicity represents a significant effort to improve immunotherapy outcomes, particularly in patient populations like MSS colorectal cancer that have historically been resistant to checkpoint inhibitors. The company's SAFEbody platform aims to address a key limitation of current antibody therapies, potentially broadening the applicability of immunotherapy and creating a competitive advantage. The AACR presentations will provide early insights into whether this strategy is translating into clinical benefit.

What we're watching

Clinical Efficacy
The data presented at AACR will be critical in assessing the early clinical efficacy of muzastotug in combination therapies, particularly given the focus on microsatellite stable colorectal cancer where existing treatments have limited effectiveness.
SAFEbody Adoption
The success of muzastotug will influence the broader adoption of Adagene’s SAFEbody platform across other antibody-based therapies, potentially impacting the company’s licensing and partnership opportunities.
Regulatory Pathway
The FDA Fast Track designation suggests an accelerated regulatory pathway, but the data presented at AACR will be closely scrutinized to determine if this timeline remains feasible.

Adagene to Present at Key Investor Conferences Amid Clinical Trial Focus

Event summary

  • Adagene’s Chief Strategy Officer, Mickael Chane-Du, will participate in investor meetings and fireside chats at the Oppenheimer Healthcare Life Sciences Conference (Feb 25) and the Leerink Global Healthcare Conference (March 8-11).
  • The company recently presented at the Guggenheim Emerging Outlook: Biotech Summit (Feb 11-12).
  • Adagene’s lead clinical program, muzastotug (ADG126), is in Phase 1b/2 and Phase 2 clinical studies for metastatic colorectal cancer (MSS CRC).
  • SAFEbody® is a registered trademark in multiple jurisdictions including the US, China, Australia, Japan, Singapore, and the EU.

The big picture

Adagene’s participation in these conferences signals an effort to actively engage with investors and highlight its SAFEbody technology, which aims to improve the safety and efficacy of antibody therapies. The company’s focus on a masked anti-CTLA-4 antibody for MSS CRC addresses a significant unmet need in a market segment with limited treatment options. The conferences provide a key venue to communicate progress and manage expectations as muzastotug advances through clinical development.

What we're watching

Clinical Progress
The success of the Phase 1b/2 and Phase 2 trials for muzastotug will be critical in validating Adagene’s SAFEbody platform and its potential to address unmet needs in MSS CRC, a challenging therapeutic area.
Investor Sentiment
Investor reception during the upcoming conferences will reveal the market’s assessment of Adagene’s technology and clinical progress, potentially influencing the company’s valuation.
Platform Adoption
The pace at which Adagene can secure additional partnerships leveraging its SAFEbody platform beyond its current collaborations will indicate the technology's broader appeal and commercial viability.

Adagene Extends Runway, Advances Muzastotug Development Amidst Collaboration Expansion

Event summary

  • Adagene reported unaudited cash and cash equivalents of $74.5 million as of December 31, 2025, projecting runway into late 2027.
  • The company shared updated Phase 1b/2 data for muzastotug + pembrolizumab at ASCO 2025, demonstrating a favorable safety profile.
  • Adagene secured a $25 million investment from Sanofi and expanded collaborations with Third Arc Bio, Exelixis, and ConjugateBio.
  • The FDA granted Fast Track designation for muzastotug in combination with pembrolizumab for MSS CRC patients.

The big picture

Adagene's strategy hinges on its SAFEbody platform, which aims to address the safety challenges associated with CTLA-4 inhibitors. The company's collaborations and recent funding underscore the growing interest in novel immunotherapy approaches for difficult-to-treat cancers like MSS CRC, a market with significant unmet need. However, the company's valuation remains sensitive to clinical trial outcomes and its ability to secure further partnerships.

What we're watching

Clinical Data
The Q1 2026 data update from the Phase 1b/2 study will be critical in assessing the efficacy and safety profile of muzastotug + pembrolizumab, potentially influencing the design of future trials.
Financial Sustainability
While the current cash runway extends to late 2027, Adagene will need to secure additional funding or demonstrate significant milestones to maintain momentum beyond that point.
Partner Synergies
The success of Adagene's collaborations with Sanofi, Roche, and others will be key to expanding the application of SAFEbody technology and accelerating pipeline development.
CID: 243